Cargando…
A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group
BACKGROUND: Postoperative adhesions occur when fibrous strands of internal scar tissue bind anatomical structures to one another. The most common cause of intra-abdominal adhesions is previous intra-abdominal surgical intervention. Up to 74% of intestinal obstructions are caused by post surgical adh...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912830/ https://www.ncbi.nlm.nih.gov/pubmed/20604918 http://dx.doi.org/10.1186/1471-2482-10-20 |
_version_ | 1782184630721445888 |
---|---|
author | Lang, Reinhold Baumann, Petra Jauch, Karl-Walter Schmoor, Claudia Weis, Christine Odermatt, Erich Knaebel, Hanns-Peter |
author_facet | Lang, Reinhold Baumann, Petra Jauch, Karl-Walter Schmoor, Claudia Weis, Christine Odermatt, Erich Knaebel, Hanns-Peter |
author_sort | Lang, Reinhold |
collection | PubMed |
description | BACKGROUND: Postoperative adhesions occur when fibrous strands of internal scar tissue bind anatomical structures to one another. The most common cause of intra-abdominal adhesions is previous intra-abdominal surgical intervention. Up to 74% of intestinal obstructions are caused by post surgical adhesions. Although a variety of methods and agents have been investigated to prevent post surgical adhesions, the problem of peritoneal adhesions remains largely unsolved. Materials serving as an adhesion barrier are much needed. METHODS/DESIGN: This is a prospective, randomised, controlled, patient blinded and observer blinded, single centre phase I-II trial, which evaluates the safety of A-Part(® )Gel as an adhesion prophylaxis after major abdominal wall surgery, in comparison to an untreated control group. 60 patients undergoing an elective median laparotomy without prior abdominal surgery are randomly allocated into two groups of a 1:1- ratio. Safety parameter and primary endpoint of the study is the occurrence of wound healing impairment or peritonitis within 28 (+10) days after surgery. The frequency of anastomotic leakage within 28 days after operation, occurrence of adverse and serious adverse events during hospital stay up to 3 months and the rate of adhesions along the scar within 3 months are defined as secondary endpoints. After hospital discharge the investigator will examine the enrolled patients at 28 (+10) days and 3 months (±14 days) after surgery. DISCUSSION: This trial aims to assess, whether the intra-peritoneal application of A-Part(® )Gel is safe and efficacious in the prevention of post-surgical adhesions after median laparotomy, in comparison to untreated controls. TRIAL REGISTRATION: NCT00646412 |
format | Text |
id | pubmed-2912830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29128302010-07-31 A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group Lang, Reinhold Baumann, Petra Jauch, Karl-Walter Schmoor, Claudia Weis, Christine Odermatt, Erich Knaebel, Hanns-Peter BMC Surg Study Protocol BACKGROUND: Postoperative adhesions occur when fibrous strands of internal scar tissue bind anatomical structures to one another. The most common cause of intra-abdominal adhesions is previous intra-abdominal surgical intervention. Up to 74% of intestinal obstructions are caused by post surgical adhesions. Although a variety of methods and agents have been investigated to prevent post surgical adhesions, the problem of peritoneal adhesions remains largely unsolved. Materials serving as an adhesion barrier are much needed. METHODS/DESIGN: This is a prospective, randomised, controlled, patient blinded and observer blinded, single centre phase I-II trial, which evaluates the safety of A-Part(® )Gel as an adhesion prophylaxis after major abdominal wall surgery, in comparison to an untreated control group. 60 patients undergoing an elective median laparotomy without prior abdominal surgery are randomly allocated into two groups of a 1:1- ratio. Safety parameter and primary endpoint of the study is the occurrence of wound healing impairment or peritonitis within 28 (+10) days after surgery. The frequency of anastomotic leakage within 28 days after operation, occurrence of adverse and serious adverse events during hospital stay up to 3 months and the rate of adhesions along the scar within 3 months are defined as secondary endpoints. After hospital discharge the investigator will examine the enrolled patients at 28 (+10) days and 3 months (±14 days) after surgery. DISCUSSION: This trial aims to assess, whether the intra-peritoneal application of A-Part(® )Gel is safe and efficacious in the prevention of post-surgical adhesions after median laparotomy, in comparison to untreated controls. TRIAL REGISTRATION: NCT00646412 BioMed Central 2010-07-06 /pmc/articles/PMC2912830/ /pubmed/20604918 http://dx.doi.org/10.1186/1471-2482-10-20 Text en Copyright ©2010 Lang et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Study Protocol Lang, Reinhold Baumann, Petra Jauch, Karl-Walter Schmoor, Claudia Weis, Christine Odermatt, Erich Knaebel, Hanns-Peter A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group |
title | A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group |
title_full | A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group |
title_fullStr | A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group |
title_full_unstemmed | A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group |
title_short | A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group |
title_sort | prospective, randomised, controlled, double-blind phase i-ii clinical trial on the safety of a-part(® )gel as adhesion prophylaxis after major abdominal surgery versus non-treated group |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912830/ https://www.ncbi.nlm.nih.gov/pubmed/20604918 http://dx.doi.org/10.1186/1471-2482-10-20 |
work_keys_str_mv | AT langreinhold aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup AT baumannpetra aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup AT jauchkarlwalter aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup AT schmoorclaudia aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup AT weischristine aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup AT odermatterich aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup AT knaebelhannspeter aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup AT langreinhold prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup AT baumannpetra prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup AT jauchkarlwalter prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup AT schmoorclaudia prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup AT weischristine prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup AT odermatterich prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup AT knaebelhannspeter prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup |